Company Overview
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States and Europe. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures; and LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. Catheter Precision, Inc. was formerly known as Catheter Robotics Inc. The company is based in Fort Mill, South Carolina.
Recent Developments
- Dec 2025 Revenue of $819.00K (+95.0% YoY); net profit $-17.18M.
- Trailing 12 Months Year-on-year growth — revenue +380.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -24.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -24.52% |
| 1 Year: | 380.70% |
Stock Price Performance
| 1 Year: | -93.89% |
| 6 Months: | -85.99% |
| 3 Months: | -80.83% |
| 1 Month: | -26.85% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -24.5% CAGR over 5 years.
- Trading 95.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VTAK Catheter Precision, Inc. PHARMA | 0.20 | -0.05 | $721.89K | 0.00% | -101.91% | -111.35% | -24.52% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.29M | 969.00K | 1.24M | 2.06M | 1.75M | 2.15M | 1.91M | 1.37M | 900.00K | 68.00K | 4.00K | 9.00K | 5.00K | 9.00K | 5.00K | - | 85.00K | - | - | 82.00K | 93.00K | 96.00K | - | 143.00K | 212.00K | 226.00K | 238.00K | 432.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.00K | 14.00K | 18.00K | 20.00K | 42.00K |
| Gross Profit | 598.00K | 233.00K | 246.00K | 784.00K | -194.00K | -580.00K | -517.00K | -210.00K | -267.00K | -500.00K | -443.00K | -511.00K | -241.00K | -86.00K | -61.00K | 0 | 75.00K | 89.00K | 127.00K | 77.00K | 77.00K | 86.00K | - | 132.00K | 198.00K | 208.00K | 218.00K | 390.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.59M | 3.04M | 3.23M | 3.08M | 2.71M |
| Operating Income | -1.72M | -2.69M | -8.39M | -4.81M | -14.95M | -15.35M | -17.59M | -7.79M | -10.12M | -7.51M | -6.87M | -6.74M | -7.39M | -5.50M | -8.46M | -4.78M | -66.48M | -6.31M | -2.73M | -2.62M | -2.72M | -2.86M | - | -3.46M | -2.84M | -3.02M | -2.87M | -2.32M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.17M | -5.83M | -1.66M | -5.45M | -1.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.00K | 67.00K | 83.00K | 82.00K | 119.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.77M | -6.41M | -2.27M | -6.06M | -1.86M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -724.00K | -950.00K | 78.00K | -214.00K | -175.00K |
| Net Income | -1.72M | -2.69M | -8.39M | -4.81M | -14.67M | -15.12M | -17.42M | -7.70M | -10.12M | -7.78M | -7.24M | -5.25M | -4.30M | -5.50M | -8.45M | -4.76M | -66.40M | -1.58M | -1.93M | -2.67M | -4.22M | -4.12M | - | -4.04M | -5.46M | -2.34M | -5.34M | -1.68M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -1.28 | -33.58 | - | -0.26 | -4.36 | - | - | - | - | - | - | - | -6.81 | -7.22 | -1.70 | - | -1.39 |
| R&D Expense | 413.00K | 286.00K | 1.02M | 224.00K | 1.53M | 979.00K | 1.18M | 1.29M | 1.95M | 2.31M | 2.75M | 2.83M | 2.94M | 3.12M | 2.40M | 727.00K | 240.00K | 134.00K | 112.00K | 37.00K | 81.00K | 63.00K | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.87M | 6.26M | 7.20M | 259.00K | - | 14.00K | 442.00K | 420.00K | 819.00K |
| Cost of Revenue | - | - | - | - | - | 161.00K | 30.00K | 42.00K | 63.00K |
| Gross Profit | 1.71M | 2.05M | -1.65M | -1.91M | - | -147.00K | 412.00K | 378.00K | 756.00K |
| Operating Expenses | - | - | - | - | - | 22.64M | 17.60M | 11.62M | 12.94M |
| Operating Income | -17.76M | -31.16M | -57.73M | -35.40M | - | -22.79M | -17.18M | -11.24M | -12.18M |
| EBITDA | - | - | - | - | - | -22.37M | -68.50M | -11.30M | -17.11M |
| Interest Expense | - | - | - | - | - | - | 0 | 91.00K | 281.00K |
| Pretax Income | - | - | - | - | - | -26.86M | -70.57M | -13.50M | -19.50M |
| Tax Provision | - | - | - | - | - | 3.00K | 0 | 3.14M | -1.81M |
| Net Income | -17.77M | -30.83M | -56.96M | -36.05M | - | -26.86M | -70.57M | -16.64M | -17.18M |
| Diluted EPS | - | - | - | - | - | -4,936.20 | -2,467.72 | -126.91 | -15.90 |
| R&D Expense | 4.52M | 2.78M | 4.53M | 8.96M | 12.25M | 6.39M | 475.00K | 272.00K | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 11.27M | 74.03M | 44.08M | 33.44M | - | 16.84M | 30.74M | 27.77M | 15.86M |
| Current Assets | - | - | - | - | - | - | 16.84M | 4.16M | 3.29M | 390.00K |
| Cash & Equivalents | 3.92M | 8.24M | 64.31M | 14.58M | 23.91M | - | 15.86M | 3.56M | 2.87M | 88.00K |
| Inventory | - | - | - | - | - | - | 0 | 44.00K | 33.00K | 86.00K |
| Receivables | - | - | - | - | - | - | 0 | 137.00K | 70.00K | 155.00K |
| Total Liabilities | - | 18.88M | 7.33M | 10.93M | 12.29M | - | 7.58M | 9.54M | 16.01M | 9.21M |
| Current Liabilities | - | 2.63M | 5.95M | 6.81M | 7.76M | - | 7.58M | 2.47M | 2.23M | 3.91M |
| Long Term Debt | - | - | 850.00K | 558.00K | - | - | - | - | 1.56M | 3.08M |
| Total Debt | - | - | - | - | - | - | 0 | 372.00K | 1.85M | 3.85M |
| Total Equity | -380.00K | -7.62M | 66.73M | 33.15M | 21.15M | - | 9.26M | 21.19M | 11.76M | 7.05M |
| Shares Outstanding | - | - | - | - | - | - | 11.37K | 36.98K | 421.30K | 1.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.52M | -18.51M | -33.17M | -28.30M | - | -22.57M | -20.62M | -9.27M | -8.30M |
| Investing Cash Flow | -547.00K | -582.00K | -16.03M | 15.93M | - | 21.00K | -61.00K | -67.00K | 167.00K |
| Financing Cash Flow | 10.39M | 75.17M | -526.00K | 21.69M | - | 23.36M | 8.39M | 8.65M | 5.34M |
| Capital Expenditure | -547.00K | -582.00K | -268.00K | -67.00K | - | -17.00K | -76.00K | -67.00K | -133.00K |
| Free Cash Flow | -6.07M | -19.09M | -33.44M | -28.37M | - | -22.59M | -20.70M | -9.34M | -8.43M |
| Net Change in Cash | - | - | - | - | - | 814.00K | -12.29M | -692.00K | -2.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 29.0% | 32.8% | -22.9% | -738.6% | - | -1,050.0% | 93.2% | 90.0% | 92.3% |
| Operating Margin % | -302.6% | -498.0% | -801.9% | -13,668.3% | - | -162,778.6% | -3,888.0% | -2,676.9% | -1,487.3% |
| Net Margin % | -302.6% | -492.8% | -791.2% | -13,917.0% | - | -191,892.9% | -15,966.5% | -3,962.6% | -2,098.0% |
| ROE % | 233.3% | -46.2% | -171.8% | -170.4% | - | -290.1% | -333.0% | -141.6% | -243.6% |
| ROCE % | -205.7% | -45.8% | -154.9% | -137.9% | - | -246.1% | -60.8% | -44.0% | -101.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Virtu Financial LLC | 0.10% | 19.86K | $2.98K |
| 2 | UBS Group AG | 0.09% | 17.06K | $2.56K |
| 3 | Geode Capital Management, LLC | 0.06% | 11.98K | $1.80K |
| 4 | Tower Research Capital LLC (TRC) | 0.05% | 9.45K | $1.42K |
| 5 | Osaic Holdings Inc. | 0.05% | 8.54K | $1.28K |
| 6 | Citigroup Inc. | - | 22 | $3 |
| 7 | Allworth Financial LP | - | 300 | $45 |
| 8 | Purpose Unlimited Inc. | - | 13 | $1 |
| 9 | Harbour Investments, Inc. | - | 8 | $1 |
| 10 | SBI Securities Co., Ltd. | - | 5 | $0 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VTAK
Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean
Landmark international milestone unlocks significant new markets and broadens Flyte’s addressable aviation footprint beyond the United StatesNew capabilities connect Flyte’s growing Florida network with high-demand leisure and resort destin…
VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
Flyte Vision Jet Segment up 61% sequentially over Q1, 2026, contributing $767,000 MedTech segment up 27% over Q2 2025 FORT MILL, S.C., July 15, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today announced prelimi…
Catheter Precision, Inc. Announces Issuance of Two Key Patents
New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure TechnologyFORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device company focused on developin…
Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany
Received First LockeT Purchase Order Through Cardinal Health which serves approximately 90% of U.S. Hospitals though its Medical Products business Johns Hopkins Hospital, a world-renowned academic medical center, Places First Order for Lock…
Flyte Partners with FullPAC to Bring Regional Aviation to the $11.4 Billion U.S. Political Campaign Market
Strategic Partnership Positions Flyte as the Premier Regional Aviation Solution for Statewide Campaigns While Expanding Access to More Than 5,000 Candidates, SuperPACs and Political Organizations FullPAC (NASDAQ Reserved Ticker: GOTV) to In…
Flyte Partners with The Nucleus Network for Inaugural Flagship Founder & Investor Event
Strategic Partnership Places Flyte at the Center of One of the Nation's Premier Communities of Founders, Investors, and Operators Collaboration Reflects Flyte's Continued Commitment to Building Relationships Within the Entrepreneurial and V…
VTAK — Frequently Asked Questions
What is the current share price of Catheter Precision, Inc. (VTAK)?
As of 2026-09-19 21:16 PDT, Catheter Precision, Inc. (VTAK) trades at $0.20 on NYSE American. Its 52-week range is $0.20 to $4.25.
What is the market capitalisation of VTAK?
Catheter Precision, Inc. (VTAK) has a market capitalisation of $721.89K on NYSE American.
What is the P/E ratio of VTAK?
VTAK trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.03.
What is the return on equity (ROE) of VTAK?
VTAK has a return on equity (ROE) of -111.35%. Its return on capital employed (ROCE) is -101.91%.
Is VTAK a good stock to buy?
This page provides a data-driven analysis of Catheter Precision, Inc. (VTAK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.